L'intérêt à découvert pour Trevi Therapeutics donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Trevi Therapeutics. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Trevi Therapeutics (NASDAQ:TRVI) Stock, Rapport sur les intérêts à découvert

TREVI THERAPEUTICS INC

Trevi Therapeutics

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.

Trevi Therapeutics Inc

Carpenter Tech (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRS#NYSE">CRS</a>) has outperformed the market over the past 15 years by 1.55% on an annualized basis producing an average annual return of 13.53%. Currently, Carpenter Tech has a market capitalization of $11.51 billion. 
Buying $1000 In CRS: If an investor had bought $1000 of CRS stock 15 years ago, it would be worth $6,239.61 today based on a price of $231.24 for CRS at the time of writing.
<h3>Carpenter Tech's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747235712_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

Here's How Much You Would Have Made Owning Carpenter Tech Stock In The Last 15 Years

TMDE

TMD Energy Shares Resumed Trade

RBC Capital analyst Karl Green reiterates Aramark (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARMK#NYSE">ARMK</a>) with a Outperform and maintains $47 price target.

Price Target

Reiteration

Analyst Ratings

ARMK

RBC Capital Reiterates Outperform on Aramark, Maintains $47 Price Target

Hims &amp; Hers Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) shares fell 3.09% Wednesday morning to $62.02, giving back some of the recent gains following its strong first-quarter earnings report.
Despite the pullback, the stock remains up an impressive 115% over the past month as investor enthusiasm around the company's growth story continues.
What To Know: Last week, Hims &amp; Hers <a href="https://www.benzinga.com/general/health-care/25/05/45208186/hims-hers-health-q1-earnings-revenue-jumps-111-subscribers-up-38-q2-guidance-falls-short-of-estimates-shares-slide">reported</a> first-quarter revenue of $586 million, a 111% increase year over year and well above Wall Street expectations.
Read Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/05/45406701/super-micro-computer-stock-is-surging-again-whats-going-on">Super Micro Computer Stock Is Surging Again: What&#8217;s Going On?</a>
Earnings per share came in at 20 cents, beating the consensus estimate of 12 cents. The company also reported subscriber growth of 38%, reaching 2.4 million.
While Hims issued a <a href="https://www.benzinga.com/general/health-care/25/05/45208186/hims-hers-health-q1-earnings-revenue-jumps-111-subscribers-up-38-q2-guidance-falls-short-of-estimates-shares-slide">cautious</a> second-quarter revenue forecast of $530 to $550 million, falling short of the $564.6 million analysts had projected, it reaffirmed its full-year guidance and long-term goal of $6.5 billion in annual revenue by 2030.
Last Thursday, the company <a href="https://www.benzinga.com/pressreleases/25/05/b45307801/hims-hers-health-inc-prices-upsized-870-0-million-convertible-senior-notes-offering-to-accelerate-">announced</a> an upsized $870 million convertible note offering due in 2030, aimed at funding international expansion and strategic initiatives. The offering includes capped call features to reduce dilution and carries a conversion price of $70.67.
Read Also: <a href="https://www.benzinga.com/news/25/05/45408603/why-quoin-pharmaceuticals-qnrx-stock-is-exploding-higher-wednesday">Why Quoin Pharmaceuticals Stock Is Exploding Higher Wednesday</a>
<h2 class="wp-block-heading">How To Buy HIMS Stock</h2>
By now you're likely curious about how to participate in the market for Hims &amp; Hers Health &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, HIMS has a 52-week high of $72.98 and a 52-week low of $13.47.

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Hims & Hers Stock Pulls Back After Strong Q1 Earnings, 115% Gain Over Past Month

Dynatrace, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DT#NYSE">DT</a>) reported <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45401623/dynatrace-reports-fourth-quarter-and-full-year-fiscal-2025-financial-results" rel="noreferrer noopener">fourth-quarter 2025</a> results on Wednesday.
The company&nbsp;reported quarterly revenue growth of 17% year-over-year to $445.17 million, beating the analyst consensus estimate of $434.78 million.
Adjusted EPS was $0.33, up from $0.30,&nbsp;beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">analyst consensus estimate</a> of $0.30.
Also Read: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45357365/salesforce-sales-cloud-ai-integration-and-cloud-upsells-drive-analyst-confidence-in-long-term-growth" target="_blank" rel="noreferrer noopener">Salesforce Sales Cloud, AI Integration, And Cloud Upsells Drive Analyst Confidence In Long-Term Growth</a>
The stock price gained after the report.
Annual Recurring Revenue (ARR) increased by 15% Y/Y or 17% in constant currency. Revenues from Subscription rose 18% Y/Y to $423.57 million.
The adjusted operating margin expanded 100 bps to 26%, with operating income up 24% Y/Y to $117.89 million.
As of March-end, Dynatrace held $1.11 billion in cash and equivalents.
During the fourth quarter, Dynatrace repurchased 0.79 million shares for approximately&nbsp;$43 million&nbsp;under its&nbsp;$500 million&nbsp;share repurchase program.
Q1 Outlook:&nbsp;Dynatrace expects revenue of $465.00 million-$470.00 million (<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">analyst consensus</a> $454.51 million). Dynatrace expects adjusted EPS of&nbsp;$0.37-$0.38 (consensus estimate $0.35).
2026 Outlook:&nbsp;Dynatrace expects revenue of $1.950 billion-$1.965 billion versus the analyst consensus of $1.940 billion. ARR is expected to be $1.975 billion-$1.990 billion.
Dynatrace expects adjusted EPS of $1.56-$1.59 versus the consensus estimate of $1.54.
Price Action: DT shares traded higher by 4.8% at $53.00 at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/tech/25/05/45379380/can-corning-broadcom-deal-transform-ais-data-center-future" target="_blank" rel="noreferrer noopener">Can Corning-Broadcom Deal Transform AI&#8217;s Data Center Future?</a></li>
</ul>
Photo: Shutterstock

Earnings

Guidance

Dynatrace Delivers Double Beat, Raises The Bar For 2026

ANTA

Antalpha Platform Shares Halted On Circuit Breaker To The Upside At $16.51/Share

RBC Capital analyst Brian Abrahams reiterates Applied Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLT#NASDAQ">APLT</a>) with a Sector Perform and maintains $1.5 price target.

APLT

RBC Capital Reiterates Sector Perform on Applied Therapeutics, Maintains $1.5 Price Target

Solana (SOL) climbed <a href="https://www.benzinga.com/money/how-to-buy-solana#:~:text=Make%20Your%20Purchase&amp;text=To%20complete%20the%20transaction%2C%20head,you%20would%20like%20to%20purchase.">6.2% over 24 hours to $181.54</a>, outpacing the broader crypto market&#8217;s 12.7% uptick this week. The push leaves SOL up 23.4% on the week, and 37.14% over the past month, according to CoinMarketCap.
The surge comes on the heel of the U.S. Securities and Exchange Commission&#8217;s (SEC) delay of its decision on Grayscale&#8217;s proposed Solana ETF, signaling renewed bullish momentum in the wake of improving on‑chain fundamentals, ecosystem growth, and growing investor appetite.
Don't Miss:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/go/plus-500-crypto-in-content">Trade crypto futures on Plus500 with up to $200 in bonuses</a> — no wallets, just price speculation and free paper trading to practice different strategies.</li>
<li>New to trading crypto? <a href="http://coinbase-consumer.sjv.io/m5ALXy">Get up to $400 in rewards for successfully completing short educational courses and placing your first qualifying trade</a> on Coinbase.</li>
</ul>
According to BeInCrypto, the SEC&#8217;s filing emphasized that the deferral &#8220;does not indicate any conclusions&#8221; and invited public comment on the proposed rule change—muting immediate price fallout as analysts expect approval later this year.
Meanwhile, big players are quietly stacking up their SOL stashes. Nasdaq‑listed DeFi Development Corp. announced that it added 172,670 SOL (about $23.6 million at an average $136.81 price) to its treasury, bringing its total holdings to nearly 595,000 SOL (worth $102.7 million). It&#8217;s the firm&#8217;s largest single acquisition to date, a concrete vote of confidence in Solana&#8217;s long‑term scalability and yield potential.
On the retail front, Solana&#8217;s meme‑coin scene is back in the spotlight. According to Decrypt, a trader turned a modest $332 wager on Gooncoin (a Solana‑based meme token) into $190,000 in a matter of days. It&#8217;s an extreme example, but it highlights how Solana&#8217;s low fees and fast block times have reignited speculative fervor. This also highlights how hype and liquidity are converging to fuel outsized short‑term returns within Solana&#8217;s fringe markets.
Digging deeper, the network&#8217;s health metrics underscore that this isn&#8217;t just hype. CoinMarketCap found that the daily active addresses are approaching multi‑month highs. Meanwhile, total value locked (TVL) in Solana‑based DeFi protocols continues to climb, exceeding that of all Ethereum layer 2s combined, a sign that genuine user adoption is underpinning the price moves, not just thrill‑seeking traders.
Solana isn&#8217;t stopping there. According to BitcoinInfoNews.com, the network is forging new speed‑optimized partnerships to bolster on‑chain payments, enabling fast, low‑cost transactions at scale. These alliances position SOL as more than a DeFi play, and usher it into real‑world use cases in micropayments and tokenized commerce.
Looking ahead, keep an eye on the $185 level as the next resistance hurdle. A sustained break above it could send SOL toward the $200 to $220 zone, while failure to hold current gains may trigger a dip back to the $172 to $175 range. The ultimate catalyst may be an eventual green light for a Solana ETF, and upcoming protocol upgrades, such as improvements to cross‑chain bridges and smart‑contract tooling.
Solana&#8217;s price action splashed with vibrant retail activity, institutional endorsements in the background, and a quietly strengthening network infrastructure, paints a compelling picture. While regulatory roadblocks may slow the pace, the pieces are falling into place for a bullish second half of 2025.
More Opportunities:
<ul class="wp-block-list">
<li>Grow your IRA or 401(k) with Crypto – <a href="https://info.irafinancial.com/lp/irafi-crypto/?utm_source=benzinga.com&amp;utm_medium=affiliate&amp;utm_campaign=y2">unlock the power of alternative investments including a Crypto IRA within your retirement account</a>.</li>
<li>Trade, earn, and grow your crypto portfolio with Crypto.com — <a href="https://www.benzinga.com/go/crypto-com-signup-bonus">plus receive up to $500 worth of rewards in the most popular tokens if you're a new customer</a>.</li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Solana Price Jumps 6% amid ETF delay and meme-coin mania

WIIM

HYPR

Hyperfine shares are trading lower after the company reported worse-than-expected Q1 sales results and cut its FY25 sales guidance below estimates. Also, Wells Fargo maintained an Equal-Weight rating on the stock and lowered its price target from $1.29 to $0.68.

IPOs

Antalpha Platform IPO Opens For Trade At $15.01/Share; IPO Priced At $12.80/Share On 3.85M Shares

Goldman Sachs analyst John Mackay maintains Venture Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VG#NYSE">VG</a>) with a Buy and lowers the price target from $20 to $17.5.

Goldman Sachs Maintains Buy on Venture Global, Lowers Price Target to $17.5

ELMD

Electromed shares are trading lower after the company reported worse-than-expected Q3 sales results.

VRCA

Verrica Pharmaceuticals shares are trading lower. The company reported Q1 financial results.

Goldman Sachs analyst Caitlin Burrows maintains Safehold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAFE#NYSE">SAFE</a>) with a Buy and lowers the price target from $28 to $25.

SAFE

Goldman Sachs Maintains Buy on Safehold, Lowers Price Target to $25

LXRX

Lexicon Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q1 sales results.

Goldman Sachs analyst Eric Sheridan maintains Roblox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) with a Neutral and raises the price target from $63 to $80.

RBLX

Goldman Sachs Maintains Neutral on Roblox, Raises Price Target to $80

SLND

Southland Holdings shares are trading higher after the company reported better-than-expected Q1 financial results.

RBC Capital analyst Luca Issi reiterates Allogene Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLO#NASDAQ">ALLO</a>) with a Outperform and maintains $10 price target.

ALLO

RBC Capital Reiterates Outperform on Allogene Therapeutics, Maintains $10 Price Target

Barclays analyst Gena Wang maintains Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) with a Overweight and lowers the price target from $9 to $5.

SGMO

Barclays Maintains Overweight on Sangamo Therapeutics, Lowers Price Target to $5

PTIX

Protagenic Therapeutics shares are trading lower. The company reported Q1 financial results.

Press Releases

Trevi Therapeutics Completes Enrollment for Phase 2b CORAL Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough

Trevi Therapeutics to Participate in Upcoming March Investor Conferences

Trevi Therapeutics to Host Conference Call and Webcast on March 10th to Share Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

Trevi Therapeutics to Report Fourth Quarter and Year End 2024 Financial Results and Provide a Corporate Update on March 18, 2025

Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates

Management

Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

Trevi Therapeutics to Participate in Upcoming April Investor Conferences

Trevi Therapeutics to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 8, 2025

Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

Comments

Trevi Therapeutics

Intérêt court

Trevi Therapeutics (NASDAQ:TRVI) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL